These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34265108)

  • 1. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
    Suezawa M; Dainichi T; Kaku Y; Izumi M; Kataoka K; Ishii N; Koga H; Izumi K; Nishie W
    J Dermatol; 2021 Oct; 48(10):1584-1587. PubMed ID: 34265108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 4. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Zhang S; Han X; Ji L
    Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center.
    Nakagawa Y; Toyoda M; Saito N; Kaneyama N; Shimizu T; Mabuchi T; Fukagawa M
    Intern Med; 2023 Jun; 62(12):1715-1722. PubMed ID: 36328578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symmetrical Skin Lesions on the Gluteal Region in a Patient with Anti-Laminin-332 Mucous Membrane Pemphigoid.
    Maki N; Demitsu T; Nagato H; Okada O; Yoneda K; Hashimoto T; Hasunuma N; Osada I; Manabe M
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):105-107. PubMed ID: 34477077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.